ATP4A: A Promising Drug Target for Gastric Acid Secretion and Cellular Communication

Target Name: ATP4A

NCBI ID: G495

ATP4A

ATP4A: A Promising Drug Target for Gastric Acid Secretion and Cellular Communication

Introduction

Gastric acid secretion is a crucial function in the digestive system, playing a vital role in the digestive process. The gastric H+/K+ ATPase alpha subunit (ATP4A) is a protein that is expressed in the stomach lining and is responsible for the production of gastric acid. Abnormalities in ATP4A function have been implicated in a variety of gastrointestinal disorders, including peptic ulcers, inflammatory bowel disease, and gastroesophageal reflux disease (GERD). As a result, targeting ATP4A has emerged as a promising strategy for the development of new treatments for these debilitating conditions. In this article, we will explore the biology of ATP4A and its potential as a drug target.

The biology of ATP4A

ATP4A is a member of the ATPase family, a superfamily of transmembrane proteins that are characterized by the presence of an ATP-binding subunit and a catalytic subunit. The ATPase subunit is responsible for generating ATP fromADP through a catalytic cycle of ATP-gene-mediated cross-phosphorylation. The catalytic subunit is responsible for the catalytic activity of the ATPase and is composed of a catalytic domain and a flexible linker region.

In the context of gastric acid secretion, ATP4A is expressed in the stomach lining and is involved in the production of gastric acid.ATP4A is a key component of the acid secretion granule, which is a specialized structure that contains the ATP4A protein and other components involved in acid production. The acid secretion granule is organized in a hierarchical manner, with the ATP4A protein located at the bottom and the proton motive force (PMF) at the top. When PMF binds to the ATP4A protein, it activates the enzyme and initiates the production of gastric acid.

Mutations in ATP4A have been implicated in a variety of gastrointestinal disorders. For example, individuals with the genetic condition known as 鈥渁tp4a null鈥? have an inability to produce gastric acid and are at increased risk of developing peptic ulcers. In addition, mutations in the ATP4A gene have been implicated in the development of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.

Targeting ATP4A as a drug

The therapeutic potential applications of targeting ATP4A are vast. In addition to treating gastrointestinal disorders, targeting ATP4A may also be a promising strategy for treating other conditions that are caused by abnormalities in ATP4A function.

One approach to targeting ATP4A is to develop drugs that specifically inhibit the activity of ATP4A. This could involve inhibiting the activity of the ATP4A protein itself or modifying the activity of the PMF.such as by blocking the interaction between PMF and ATP4A, or by inhibiting the production of PMF.

Another approach to targeting ATP4A is to target the downstream consequences of ATP4A function, such as the production of PMF. This could involve inhibiting the production of PMF or modifying its activity, such as by blocking the interaction between PMF and ATP4A.

In addition to these approaches, targeting ATP4A may also involve modifying the cellular signaling pathways that are involved in ATP4A function. For example, modifying the levels of intracellular signaling molecules, such as the production of reactive oxygen species (ROS), may be

Protein Name: ATPase H+/K+ Transporting Subunit Alpha

Functions: The catalytic subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells. Uses ATP as an energy source to pump H(+) ions to the gastric lumen while transporting K(+) ion from the lumen into the cell (By similarity). Remarkably generates a million-fold proton gradient across the gastric parietal cell membrane, acidifying the gastric juice down to pH 1 (By similarity). Within a transport cycle, the transfer of a H(+) ion across the membrane is coupled to ATP hydrolysis and is associated with a transient phosphorylation that shifts the pump conformation from inward-facing (E1) to outward-facing state (E2). The release of the H(+) ion in the stomach lumen is followed by binding of K(+) ion converting the pump conformation back to the E1 state (By similarity)

The "ATP4A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP4A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets